| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6801011 | Journal of Psychiatric Research | 2014 | 9 Pages |
Abstract
To improve treatment success rates and quality-adjusted life years, SSRIs can be considered the most cost-effective option. Future research is needed to further clarify the impacts of physical comorbidities and other associated factors on the cost-effectiveness and cost-utility of pharmacological treatments in patients with depression.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Yi-Ju Pan, Kuei-Hong Kuo, Hung-Yu Chan, Paul McCrone,